

Nischarin expression may have differing roles in male and female melanoma patients

Marija Ostojić^{1*}, Marko Jevrić^{2*}, Olivera Mitrović-Ajtić³, Miljana Tanić¹, Milena Čavić¹, Tatjana Srdić-Rajić^{1#}, Jelena Grahovac^{1#}

¹ Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

² Department of Surgery, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

³ Department of Molecular Oncology, Institute for Medical Research, Belgrade, Serbia


* Marija Ostojić and Marko Jevrić contributed equally to this work.

Corresponding authors:


Jelena Grahovac, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia. E-mail: jelena.grahovac@ncrc.ac.rs

Tatjana Srdić-Rajić, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia. E-mail: tatjana.srdic@ncrc.ac.rs

a




b




Supplemental Fig. S1 The effect of nischarin mRNA expression on melanoma patients' overall survival in GSE46517 dataset. (a) Primary melanoma samples from GSE46517 dataset were divided into “high” and “low NISCH” groups for both sexes based on the median value of NISCH expression. **(b)** Same group of samples was used to investigate the difference between NISCH mRNA levels in females and males using t-test



a




b




c




d



e



f



Supplemental Fig. S2 Infiltration estimation for TCGA SKCM primary tumor samples. Samples were divided into four groups based on patient sex and the best cut-off NISCH expression levels used in survival analysis. Results from (a) EPIC, (b) quanTiseq, (c) xCell, (d) MCP-counter, (e) TIMER, and (f) CIBERSORT-ABS were analyzed using one-way ANOVA with Tukey's multiple comparisons test for each cell type. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$